I N THIS ISSUE OF THE JOURNAL. TWO IMPORTA NT PAPERS (pages 290. 295) describing the progress of the human immunodeficiency virus (HIV) epidemic in Canada are published. Changes in the demographics of this disease in the United States are well-described and document a steady shift to less advantaged groups in society including intravenous drug abusers. individuals in the sex trade and certain members of the immigrant population . The fragmentary data available to us from epidemiological studies in Canada suggest that the shift in Canada is not as marked as that observed in the United States. but the e.>..'"])ectation is that similar trends will be observed. Our knowledge of the extent of infection and impact of this virus in Canada, however. is described poorly. What do we know about the current status of this most important public health problem at the end of the 20th century?
The paper by Ricketts et al. from the Laboratory Centre for Disease Control. is reassuring. A surveillance system enrolling s ubj ects from across Canada to follow s ignificant occupational exposure to HN has failed to document prospectively any case of transmission of the viru s occupationally in Canada afte r six and one-half years. One recent anecdotal report (1) does suggest possible occupational acqui sition by a technologist early in the epidemic. before current programs to prevent transmission were in place and before this surveillance program was initiated. Studies from the United Stales (2) have documented U1al tile risk of acquiring HN infection following needlestick exposu re to a known inJected patient is 0.3 to 0 .5% . The risk likely is greater when th e exposu re allows inocu lation of greater quantities of blood. This low rate of transmission . compared with agents such as hepatitis B. reflects the low inoculum of infectious virus present in the blood of most individuals infected witil HIV. Given these reported tra nsmission rates it is not surpris ing -witi1 the numbers of e pisodes e nroll ed in tile Canadian Surveillance Study -tilat an episode of prospectively documented occupational transmission in Cana da has not been observed. The study confirms. however. U1al in
Can ada. as elsewhere. the occupational risk of transmission of HN is extraordin a rily small. This is reass uring to all of us who work in health care. The introdu ction of neeclleless devices and other programs to limit exposure to s harps and potential injuries hopefully vvill further enhance the safety of the hospital and clinic environment.
The study by Sel<la et al from Manitoba is much less reassuring: it is one of the first published unlinked seroprevalence studies in a Canadian population. This study confirms the impression from acquired immune deficiency syndrome incidence reports of Manitoba as a low prevalence area for HN infection. Th e prevalence of HN infection in screening of prenatal bloods was only 0. 72 per 10.000 compared with British Columbia (2. 7 per 10,000) or Quebec (6.1 per 10,000) . This study also suggests. for Manitoba, that HIV infection is not yet common in the parenteral drug abuser or prostitute population.
What is surprising, however. is ti1at even for a geographic area of low prevalence for HN infection. ti1e rate amon g men in Manitoba assessed for sexually transmitted diseases was 143 per 10,000. As ti1e auth ors point out. this identifies a s ubgro up of individuals who sho uld be targeted for screening progran1s. Similar studies reporting observations fro m other provinces across Can ada are essential to map the full picture of HN infection in this country. Repeated stu dies will be one means of monitoring the progress of the ep idem ic.
Recommendations for HIV screening have consiste ntly prompted inten se co ntroversy. Early in ti1e ep id em ic . there were arguments for not screening based on human rights con cerns. validity of laboratory tests and questions with respect to the individual benefit for an asymptomatic subject to know her or his s e rological status. The last two items are no longer issues. Diagnostic testing is reliable and options for current management ma k e it clear that early identification of infected individua ls is not only desirable. but essential. Provis ion of early antiretrovi ra l therapy and prophylaxis for important infections such as PnelLmocytis carinii pneumonia improves the quality of life and prolongs survival for HlV-infected subjects. Thus. there are strong medical arguments for screening of high prevalence populations . There are also public health arguments. Identification of individuals infected with HlV should allow the opportunity to educate them with respect to transmission and behaviour mod ification to prevent transmission. While this may not always be effective. early identification of infection and contact tracing must be a primary method of control.
These arguments for more intensive screening of populations \vith a high prevalence of HlV infection are compelling. In Manitoba. one group who should be encouraged to accept screening would be males being assessed for sexually transmitted diseases. High prevalence groups in other parts of the country similarly should be identified. Some elements of our society may still penalize individuals found to be HlV-infected. and individual rights must be protected. However, a more 'routine' approach to identification of HlV infection may help to demystify this disease and ameliorate some public misconceptions.
The goals we have with respect to managing HlV infection in Canada are straightforward. First, we wish to prevent transmission of the infection to noninfected individuals. While programs of education and screening may have some impact on this goal, success realistically requires development and widespread use of an 286 effective vaccine. Second , we wish to cure individuals infected \vith this virus. This currently is not achievable. Further intensive basic research to understand the virus and its biology, and to accelerate the development of antiviral therapies will be necessary to achieve this goal. Third, if we cannot cure the infection. we wish to optimize medical care for infected individuals. This requires ongoing clinical trials and assessments of new therapeutic. preventive and suppressive therapies. Appropriate medical facilities to optimize outpatient management and provision of palliative care are part of this goal. Underpinning all these efforts must be high quality. current, epidemiological data describing the progress of this epidemic in Canada and analyzing. on an ongoing basis. the changes occurring. The studies of Ricketts el al and Selda et al are important and helpful. but much further information is required.
